Abstract Acute Respiratory Distress Syndrome (ARDS) is one of the most demanding
conditions in an Intensive Care Unit (ICU). Management of analgesia and sedation in ARDS …

The rapid spread of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
has led to a global pandemic. The 2019 coronavirus disease (COVID-19) presents with a …

Pneumonia and acute respiratory distress syndrome are common and important causes of
respiratory failure in the intensive care unit with a significant impact on morbidity, mortality …

Hospitals worldwide are experiencing a shortage in essential intravenous sedative
medications. This is attributable to high number and high sedative needs of COVID-19 …

Mechanical ventilation (MV) is the cornerstone of acute respiratory distress syndrome
(ARDS) management. The use of protective ventilation is a priority in this acute phase of …

Purpose In this retrospective study, we compared inhaled sedation with isoflurane to
intravenous propofol in invasively ventilated COVID-19 patients with ARDS (Acute …

Inhaled sedation with halogenated agents, such as isoflurane or sevoflurane, is now
feasible in intensive care unit (ICU) patients through dedicated vaporisers and scavenging …

Lung-protective ventilation (LPV) has primarily focused on limiting lung injury (VILI)
secondary to overdistension and collapse [1]. Deep sedation is often required for tolerance …

Background: Volatile anesthetics were used as sedative agents in COVID-19 (Coronavirus
Disease 2019) invasively ventilated patients for their potentially beneficial pharmacological …

The pathophysiology of acute respiratory distress syndrome (ARDS) includes the
accumulation of protein-rich pulmonary edema in the air spaces and interstitial areas of the …